Cell culture media specialist Xcell Therapeutics held an IPO press conference in Yeouido, outlining its strategies and vision following its upcoming KOSDAQ listing. 

The company develops and produces media, essential nutrients for culturing cells, which are crucial in the production and efficacy of cell and gene therapies (CGT). Media significantly impact the safety, productivity, and cost-effectiveness of these therapies.

Xcell Therapeutics' flagship product is the third-generation chemically defined media, "CellCor." Unlike first-generation serum-based and second-generation serum-free media, CellCor uses only chemically identified raw materials, offering both technological and economic advantages. The company is one of the few globally with this advanced media technology.

Xcell Therapeutics currently offers six media pipelines, including CellCor MSC CD AOF for mesenchymal stem cells and CellCor EXO CD for exosomes, with plans to expand into NK, T, and iPSC cell-specific media. Post-listing, the company aims to scale its global presence, increasing its distributors from 7 to 15 and expanding to 30 countries by the end of the year. 

Additionally, Xcell Therapeutics plans to strengthen partnerships with CDMO companies and pursue white-label agreements with multinational corporations.

Xcell Therapeutics will offer approximately 1.6 million shares at a price range of 6,200 to 7,700 KRW per share, with a target IPO amount of 10 to 12.5 billion KRW. The listing is expected on KOSDAQ in July, with Daishin Securities as the lead underwriter.